MNKD Stock Cash Flow Statements

MannKind Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

MannKind Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-02-14	2009-02-14	2007-02-14

cash flows from operating activities:
net income	668,000	13,158,000	7,422,000	11,550,000	-2,014,000	10,630,000	1,401,000	1,721,000	-5,265,000	-9,795,000	-17,947,000	-14,432,000	-29,023,000	-25,998,000	-28,061,000	-4,426,000	-35,523,000	-12,916,000	-26,411,000	-11,255,000	-10,252,000	-9,322,000	-14,263,000	-10,370,000	-12,387,000	-14,883,000	-9,751,000	-24,164,000	-22,675,000	-30,385,000	-32,784,000	-32,886,000	-35,339,000	-16,324,000	53,974,000	126,521,000	-29,958,000	-24,873,000	-277,019,000	-31,857,000	-28,911,000	-30,658,000	-36,441,000	-36,519,000	-73,366,000	-52,056,000	-53,583,000	-50,818,000	-46,124,000	-40,965,000	-51,781,000	-42,834,000	-36,578,000	-38,173,000	-36,397,000	-41,525,000	-59,412,000	-119,867,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation	7,520,000	5,385,000	5,818,000	5,227,000	6,428,000	3,885,000
depreciation and amortization	2,087,000	2,106,000	2,160,000	2,119,000	1,731,000	1,361,000	1,225,000	1,137,000	1,115,000	1,058,000		1,769,000	1,411,000	1,324,000																																							3,647,000	3,696,000	3,815,000	4,119,000	4,515,000	2,138,000
loss on settlement of debt
gain on foreign currency transaction	5,363,000	2,509,000						-2,065,000	251,000	954,000
write-off of inventory	4,592,000	466,000	1,946,000	291,000	589,000	1,029,000	915,000	300,000	943,000	2,416,000	834,000	917,000							0	0	0	496,000					420,000	1,013,000	177,000	602,000
amortization of right-of-use assets	531,000	544,000	528,000	493,000	319,000	328,000	323,000	321,000	319,000	338,000	332,000	324,000	2,042,000	289,000	753,000	-163,000	359,000	309,000	298,000	303,000	294,000	282,000	279,000	285,000	223,000	395,000
amortization of debt discount and issuance costs	109,000	109,000	313,000	417,000	415,000	501,000	515,000	629,000	472,000	469,000
interest on liability for sale of future royalties	3,475,000	3,577,000	3,452,000	4,089,000	4,383,000	4,248,000
sold portion of royalty revenue	-3,123,000	-3,000,000	-2,701,000	-2,709,000
net accretion of investments	-759,000	-919,000		-1,656,000	-1,125,000	-984,000
loss on available-for-sale securities																																																			0	0	0	117,000
loss on estimated returns of acquired product			0	0	275,000	1,169,000
interest on mann group convertible note			0	0	1,000	55,000
other			-290,000	0	0	49,000	94,000	-188,000	-295,000	50,000									0	0	0	19,000	4,000			-1,000	-131,000	0	-4,000	110,000	-147,000	133,000			-698,000	0	21,000	696,000	45,000	1,000	1,000	-7,000	-3,000				5,000	-1,000	0	-2,000	2,000	3,000	-8,000	1,000		5,000
changes in operating assets and liabilities:
accounts receivable	1,758,000	-17,096,000	6,380,000	5,162,000	-3,434,000	-5,456,000	7,366,000	5,967,000	-8,075,000	-2,913,000	6,692,000	-8,463,000	-5,207,000	-4,829,000	4,451,000	-3,140,000	-2,732,000	645,000	-83,000	-769,000	1,808,000	-1,661,000	580,000	881,000	-1,215,000	258,000	-1,265,000	96,000	-1,298,000	1,128,000	-985,000	-492,000	-874,000	-136,000	2,812,000
inventory	-4,191,000	-1,472,000	-3,169,000	-2,201,000	1,100,000	1,074,000	-2,343,000	-2,127,000	-4,236,000	-2,641,000	-4,333,000	1,383,000	-1,828,000	-892,000	-1,572,000	0	-2,432,000	-77,000	-92,000	-1,058,000	-592,000	428,000	-463,000	271,000	-243,000	-123,000	-1,232,000	-122,000	38,000	-1,836,000	-2,499,000	43,000	526,000	-1,367,000	2,793,000	-2,258,000			-12,702,000	-3,586,000	-3,027,000	-7,119,000
prepaid expenses and other current assets	-2,327,000	-3,044,000	-132,000	-1,148,000	-2,020,000	-3,274,000	-905,000	-3,285,000	-7,657,000	2,426,000	-7,465,000	-7,852,000	235,000	-470,000	-255,000	397,000	-858,000	356,000	1,152,000	-2,658,000	364,000	988,000	695,000	-878,000	-314,000	164,000	459,000	-445,000	-216,000	656,000	51,000	-497,000	944,000	856,000	170,000	-3,111,000	1,384,000	1,211,000	6,506,000	849,000	2,299,000	3,831,000	47,000	-16,557,000	-56,000	1,845,000	-257,000	-2,045,000	647,000	690,000	16,462,000	-2,276,000	-16,096,000	365,000	335,000	370,000	1,076,000	2,682,000
other assets	136,000	-1,661,000	-749,000	-612,000	-1,895,000	-314,000	298,000	-15,000			1,091,000	-127,000	-121,000	-320,000	301,000	-237,000	-105,000	-97,000	36,000	109,000	42,000	40,000					0	121,000	41,000	38,000	22,000	41,000	86,000	39,000	54,000	545,000	-152,000	-86,000	822,000	194,000	6,000	-872,000	-485,000	1,000											0	87,000		-182,000
accounts payable	5,216,000	-1,751,000	348,000	-3,112,000	2,407,000	-2,431,000	-7,175,000	-373,000	3,238,000	2,837,000	1,180,000	2,049,000	-878,000	1,745,000	-2,572,000	2,042,000	780,000	1,124,000	-215,000	-24,000	-910,000	1,942,000	-6,875,000	4,128,000	555,000	1,599,000	-436,000	-3,422,000	4,261,000	-2,008,000	1,701,000	-1,258,000	5,022,000	-1,665,000	-1,830,000	2,244,000	2,267,000	-14,799,000	11,111,000	-462,000	1,946,000	-4,182,000	-10,070,000	12,125,000	2,605,000	-1,038,000	858,000	-955,000	-50,000	-924,000	1,570,000	-2,770,000	2,957,000	-1,713,000	2,793,000	-218,000	-3,194,000	15,636,000
accrued expenses and other current liabilities	-9,467,000	134,000	2,106,000	-3,046,000	-2,433,000	670,000	10,430,000	579,000	1,572,000	-5,975,000	2,212,000	-2,801,000	-644,000	510,000	5,343,000	256,000	-5,073,000	8,288,000	2,705,000	1,984,000	-3,223,000	1,880,000	3,632,000	-594,000	-1,876,000	2,336,000	1,689,000	-258,000	-1,857,000	2,675,000	43,000	3,372,000	-1,560,000	1,077,000	-6,227,000	3,912,000	2,175,000	488,000	-6,545,000	1,878,000	2,860,000	-10,660,000	5,279,000	312,000	3,389,000	-6,704,000	150,000	1,127,000	1,683,000	715,000	-21,823,000	3,590,000	31,420,000	1,888,000	5,184,000	3,850,000	-10,803,000	-8,371,000
deferred revenue	-2,691,000	-4,450,000	-8,101,000	-1,868,000	-1,806,000	-3,537,000	5,740,000	9,402,000	15,762,000	8,558,000	5,635,000	2,353,000	4,006,000	7,053,000	4,802,000	-6,147,000	-5,791,000	-7,431,000	4,371,000	-6,478,000	4,432,000	-8,235,000	6,004,000	-5,926,000	-7,481,000	686,000					17,000				1,405,000
recognized loss on purchase commitments			-1,000	1,000	-2,021,000	-669,000	-2,614,000	-2,524,000	-2,212,000	-2,074,000	-1,403,000	-1,378,000	-1,426,000	-1,502,000	-920,000	-1,336,000	-1,257,000	-2,379,000	-3,516,000	1,000			0	-411,000	-2,021,000	-1,963,000		-365,000	-5,653,000	-147,000	-4,097,000	-148,000	34,000	-534,000	38,199,000
operating lease liabilities	53,000	-972,000	-885,000	-861,000	-314,000	-232,000	-607,000	-625,000	-467,000	-686,000	-324,000	-544,000	-1,869,000	-572,000	-768,000	187,000	-1,221,000	-333,000	775,000	-686,000	-677,000	-724,000	-608,000
net cash from operating activities	8,950,000	-6,377,000	22,644,000	9,331,000	3,833,000	6,703,000	21,678,000	8,664,000	2,596,000	1,156,000	-2,376,000	-28,073,000	-31,982,000	-18,248,000	-12,347,000	-15,184,000	-21,447,000	-12,731,000	235,000	-13,460,000	-3,684,000	-11,219,000	-5,107,000	-52,051,000	-19,728,000	-11,597,000	24,988,000	-13,919,000	-27,150,000	-21,650,000	-29,981,000	-23,270,000	-20,034,000	8,507,000	-12,752,000	-23,071,000	-11,509,000	-30,758,000	-22,551,000	-19,892,000	-17,809,000	3,020,000	-35,744,000	100,238,000	-23,418,000	-36,990,000	-34,051,000	-32,910,000	-29,744,000	-32,027,000	-28,098,000	-34,258,000	-25,018,000	-32,486,000	-20,355,000	-30,704,000	-60,669,000	-102,992,000
capex	-1,117,000	-330,000	-2,896,000	-1,417,000	-2,972,000	-2,408,000	-5,874,000	-11,387,000	-16,869,000	-8,311,000	-5,096,000	-271,000	2,834,000	-5,056,000	-5,190,000	-4,246,000	-1,054,000	-976,000	-497,000	-4,000	-150,000	-150,000	-109,000	-963,000	-1,224,000	-269,000	0	0	0	0	0	0	0	0	0	0	0	-1,144,000	-316,000	-1,232,000	-4,534,000	-4,203,000	-4,963,000	-9,467,000	-8,258,000	-1,409,000	-6,166,000	-230,000	-132,000	-1,459,000	-65,000	-124,000	-125,000	-323,000	-155,000	-1,993,000	-5,622,000	-34,799,000
free cash flows	7,833,000	-6,707,000	19,748,000	7,914,000	861,000	4,295,000	15,804,000	-2,723,000	-14,273,000	-7,155,000	-7,472,000	-28,344,000	-29,148,000	-23,304,000	-17,537,000	-19,430,000	-22,501,000	-13,707,000	-262,000	-13,464,000	-3,834,000	-11,369,000	-5,216,000	-53,014,000	-20,952,000	-11,866,000	24,988,000	-13,919,000	-27,150,000	-21,650,000	-29,981,000	-23,270,000	-20,034,000	8,507,000	-12,752,000	-23,071,000	-11,509,000	-31,902,000	-22,867,000	-21,124,000	-22,343,000	-1,183,000	-40,707,000	90,771,000	-31,676,000	-38,399,000	-40,217,000	-33,140,000	-29,876,000	-33,486,000	-28,163,000	-34,382,000	-25,143,000	-32,809,000	-20,510,000	-32,697,000	-66,291,000	-137,791,000
cash flows from investing activities:
proceeds from maturities of available-for-sale securities	51,396,000	50,396,000
purchase of available-for-sale securities	-44,023,000	-44,104,000									0	0	0	-5,000,000	0	0
purchase of property and equipment	-1,117,000	-330,000	-2,896,000	-1,417,000	-2,972,000	-2,408,000	-5,874,000	-11,387,000	-16,869,000	-8,311,000	-5,096,000	-271,000	2,834,000	-5,056,000	-5,190,000	-4,246,000	-1,054,000	-976,000	-497,000	-4,000	-150,000	-150,000	-109,000	-963,000	-1,224,000	-269,000									0	0	0	-1,144,000	-316,000	-1,232,000	-4,534,000	-4,203,000	-4,963,000	-9,467,000	-8,258,000	-1,409,000	-6,166,000	-230,000	-132,000	-1,459,000	-65,000	-124,000	-125,000	-323,000	-155,000	-1,993,000	-5,622,000	-34,799,000
purchase of held-to-maturity securities
proceeds from maturities of held-to-maturity securities
proceeds from insurance claim			0	0	0	396,000	0
net cash from investing activities	6,256,000	5,962,000	48,224,000	-41,256,000	-55,180,000	-48,437,000	-7,895,000	-11,549,000	3,664,000	13,792,000	15,010,000	27,348,000	2,022,000	-39,506,000	-12,579,000	4,992,000	-112,532,000	-31,418,000	-4,480,000	-4,000	-150,000	19,850,000	-202,000	3,761,000	-1,369,000	-25,033,000	-244,000				0	0	24,000	16,651,000	0	0	0	-1,127,000	-312,000	-1,154,000	-4,534,000	-4,203,000	-14,213,000	-217,000	-8,258,000	-1,409,000	-6,166,000	-230,000	-132,000	-1,459,000	-61,000	-124,000	-84,000	-291,000	-125,000	1,835,000	178,000	-35,382,000
cash flows from financing activities:
payments for taxes related to net issuance of common stock associated with restricted stock units and stock options	-5,983,000	1,590,000	91,000	-1,511,000	-4,933,000	266,000	38,000	-1,708,000
principal payments on financing liability	-176,000	-200,000	-116,000	-79,000
proceeds from market price stock purchase plan and employee stock purchase plan			819,000	0			745,000	0
milestone payment			0				0				0				0	0																							0	1,000	0	-4,220,000
principal payments on financing lease liability				0
principal and early extinguishment payments on midcap credit facility			0	0
principal and early extinguishment payments on mann group convertible note			0	0
net cash from financing activities	-5,510,000	1,390,000	-86,900,000	-2,342,000	-44,550,000	-3,474,000	141,681,000	-283,000	-5,945,000	1,154,000	2,825,000	19,526,000	-1,776,000	813,000	97,370,000	-590,000	-51,490,000	224,977,000	18,694,000	2,640,000	28,188,000	331,000				3,000	35,967,000	-1,823,000	26,622,000	528,000	58,244,000	-22,000	15,416,000	-75,000	117,000	-5,132,000	47,589,000	464,000	49,009,000	-53,213,000	8,686,000	1,186,000	-1,667,000	31,230,000	37,131,000	3,368,000	17,204,000	98,414,000	30,400,000	-349,000	88,234,000	91,259,000	-86,365,000	86,451,000	375,000	9,720,000	59,957,000	98,000
net increase in cash, cash equivalents and restricted cash	9,696,000	975,000	-16,032,000	-34,267,000
cash, cash equivalents and restricted cash, beginning of period	0	47,076,000	0	0
cash, cash equivalents and restricted cash, end of period	9,696,000	48,051,000	-16,032,000	-34,267,000
supplemental cash flows disclosures:
interest paid in cash		3,012,000										802,000	741,000	3,600,000																																										5,504,000	12,000
income taxes paid in cash		207,000
non-cash investing and financing activities:
non-cash construction-in-progress, property and equipment		144,000
loss on disposal of fixed assets
gain on bargain purchase			0
net amortization of investments
(gain) loss on foreign currency transaction					-529,000	-1,399,000
interest accretion on financing liability
deposits from customer															-57,000	-310,000
acquisition of v-go											-242,000	0
proceeds from sale of future royalties
issuance costs associated with sale of future royalties
principal and early extinguishment payments on senior convertible notes
proceeds from at-the-market offering																0	0	1,886,000				668,000
issuance costs associated with at-the-market offering							0	-67,000	-17,000	-24,000						0	0	-38,000				-20,000
loss on extinguishment of debt				0											0	-4,930,000												712,000	-772,000	825,000		0							0
gain on available-for-sale securities								0
purchase of held-to-maturity debt securities				-86,342,000	-119,048,000	-68,399,000	-28,579,000	-24,069,000
proceeds from held-to-maturity debt securities				46,503,000	66,840,000	21,974,000
proceeds from at-the-market-offering							0	4,105,000	1,584,000	1,198,000
proceeds from market price stock purchase plan						1,361,000						0	0	684,000					201,000	0							95,000
principal payment on financing liability						-101,000
principal payment on midcap credit facility						-5,000,000
net increase in cash and cash equivalents						-45,208,000	155,464,000	-3,168,000	315,000	16,102,000		18,801,000																					-4,594,000	25,083,000			36,080,000	-31,421,000	26,146,000	-74,259,000	-13,657,000	3,000	-51,624,000	131,251,000	5,455,000	-35,031,000	-23,013,000	65,274,000	524,000	-33,835,000	60,075,000	-944,000	-53,646,000	53,674,000	-20,105,000	-19,149,000	-534,000	-138,276,000
cash and cash equivalents, beginning of period						238,480,000	0	0	0	69,767,000		0																				0	0	22,895,000	0	0	0	59,074,000	0	0	0	120,841,000	0	0	0	70,790,000	0	0	0	61,840,000	0	0	0	2,681,000	0	66,061,000	27,648,000	263,518,000
cash and cash equivalents, end of period						193,272,000	155,464,000	-3,168,000	315,000	85,869,000		18,801,000																				-23,292,000	-4,594,000	47,978,000	-12,635,000	-28,203,000	36,080,000	27,653,000	26,146,000	-74,259,000	-13,657,000	120,844,000	-51,624,000	131,251,000	5,455,000	35,759,000	-23,013,000	65,274,000	524,000	28,005,000	60,075,000	1,734,000	-56,324,000	56,355,000	-20,105,000	46,912,000	27,114,000	125,242,000
interest on financing liability
asset impairment															0				0	0
interest on milestone right
accrued interest on mann group convertible note
proceeds from senior convertible notes
issuance costs associated with senior convertible notes															0	0	0	-7,268,000
proceeds from the sale-leaseback transaction
issuance costs associated with the sale-leaseback transaction
deposit for the sale-leaseback transaction
principal payments on mann group convertible note
payment on midcap credit facility							-5,000,000
payment of midcap credit facility prepayment penalty															0	0
stock-based compensation expense								4,601,000	5,580,000	3,655,000	2,597,000	3,622,000	4,422,000	2,806,000	3,160,000	3,179,000	3,926,000	1,935,000	1,904,000	1,294,000	2,185,000	1,128,000	891,000	1,640,000	2,673,000	999,000	1,142,000	1,563,000	2,209,000	1,943,000	1,084,000	1,247,000	1,249,000	1,267,000	1,005,000	1,502,000	1,355,000	1,273,000	2,347,000	2,600,000	1,775,000	2,003,000	1,867,000	-4,828,000	40,646,000	10,937,000	13,882,000	15,942,000	10,173,000	5,189,000	3,522,000	3,819,000	3,073,000	2,878,000	3,181,000	2,708,000		5,460,000
interest expense on mann group convertible note								56,000	54,000	55,000
interest expense on financing liability								-4,847,000	2,449,000	2,424,000	2,425,000	2,313,000	2,443,000	2,371,000
proceeds from maturity of debt securities								23,525,000	46,980,000	22,103,000	24,756,000	29,277,000	26,769,000	26,538,000
payment on financing liability								-22,000	-43,000	-72,000	-16,000	1,397,000
net issuance of common stock associated with stock options and restricted stock units										52,000
depreciation, amortization and accretion															1,220,000	1,324,000	1,016,000	655,000	510,000	534,000	567,000	538,000	565,000	-332,000	372,000	367,000	368,000	1,030,000	753,000	706,000	821,000	920,000	879,000	908,000
interest expense on mann group promissory notes																82,000	370,000	1,028,000
(gain) loss on foreign currency translation															-1,564,000	-2,068,000									1,247,000	-1,935,000	-1,361,000	-728,000
in-process research and development
accrued interest on mann group promissory notes															0	0
proceeds from sale of treasury bills																			0	0	0	20,000,000	-2,000
acquisition of in-process research and development, net of cash acquired
issuance costs associated with at the market offering																			-150,000	-37,000
proceeds from market price stock purchase plan and from employee stock purchase plan
issuance of common stock from the exercise of warrants																			0	0
proceeds from midcap credit facility																							0
proceeds from ppp loan
proceeds from the senior convertible notes															0	0	0	230,000,000
principal payments on mann group promissory notes															0	0
payment of midcap credit facility															0	0
net increase in cash and cash equivalents and restricted cash														-56,941,000	72,444,000	-10,782,000	-185,469,000	180,828,000	14,449,000	-10,824,000	24,354,000	8,962,000							-528,000	-21,122,000
cash and cash equivalents and restricted cash, beginning of period														124,184,000	0	0	0	67,163,000	0	0	0	30,222,000	0	0	0	71,684,000	0	0	0	48,355,000
cash and cash equivalents and restricted cash, end of period														67,243,000	72,444,000	-10,782,000	-185,469,000	247,991,000	14,449,000	-10,824,000	24,354,000	39,184,000	-267,000	17,205,000	-21,773,000	35,057,000	60,711,000	-15,732,000	-528,000	27,233,000
interest on milestone payment																0
interest expense on mann group promissory note
gain on foreign currency translation												-1,799,000	-4,503,000	-1,983,000				-3,838,000	4,008,000	3,927,000	1,867,000	-1,796,000	2,582,000
payment-in-kind interest on mann group promissory note
accrued interest on mann group mann group promissory note
customer deposits												-1,563,000	-5,491,000	2,104,000
purchase of debt securities												-1,658,000	-12,482,000	-55,988,000		-96,486,000	-108,478,000	-30,442,000
payment of employment taxes related to vested restricted stock units and exercise of stock options												-192,000	-377,000	129,000	240,000	-590,000	-545,000	397,000	332,000	102,000
principal payments on mann group mann group promissory note
reclassification of investments from long-term to current												19,854,000	37,423,000	14,813,000
payments on debt and interest through common stock issuance												99,000
modification of operating leases												0
addition of right-of-use asset												0
non-cash construction in progress and property and equipment												517,000	533,000	383,000		-1,029,000	1,059,000	124,000				32,000																558,000		-431,000	-471,000	1,094,000	-2,041,000	844,000	1,265,000	1,700,000	-4,667,000	918,000	742,000	3,863,000	1,165,000	564,000	1,422,000	921,000	69,000	4,371,000	7,281,000
common stock issuance to settle employee stock purchase plan liability												873,000	0	740,000				390,000	0	366,000	0	318,000	0	339,000	0	317,000
contingent milestone liability												0
premium on mann group convertible note																0
forgiveness of ppp loan
interest expense on promissory notes													86,000	116,000					1,296,000	1,316,000	1,279,000	1,257,000	1,195,000
ut owned property and equipment
payment on mann group convertible note through issuance of common stock																2,000	0	9,573,000
payment of 2024 convertible notes through common stock issuance																		5,000,000
reclassification of the ppp loan from current to long-term																		609,000
payment of mann group convertible note interest through issuance of common stock																0	0	427,000
payment of interest on 2024 convertible notes through common stock issuance																		143,000
amortization of financing liability
proceeds from sale of debt securities
proceeds from market price stock purchase																0
interest paid in cash, net of amounts capitalized																3,818,000	5,623,000	1,094,000	697,000	1,041,000	935,000	885,000					864,000	1,035,000	0	1,860,000	1,355,000	2,232,000	1,591,000	2,550,000		2,590,000	1,895,000	2,713,000		4,795,000	1,895,000	4,749,000		4,444,000	618,000	4,678,000		2,856,000	2,143,000	2,863,000		2,875,000	2,156,000	2,595,000	2,156,000
right-of-use asset modification
addition of operating lease liability
operating lease liability modification
payment of 2024 convertible notes through issuance of common stock																0
issuance of common stock under employee stock purchase plan																700,000
payment of interest on 2024 convertible notes through issuance of common stock																0
payment of principal on senior convertible notes through issuance of common stock
receivable from at-the-market offering
payment-in-kind interest on promissory notes																							0
gain on extinguishment of debt
loss on warrant transactions
purchase of treasury bills																							-91,000
purchase of limited liability company ownership interest																							0
proceeds from at the market offering																			8,311,000	2,575,000
proceeds from paycheck protection program loan																			0	0
proceeds from promissory notes																							0
principal payments on promissory notes
principal payments on senior convertible notes
principal payments on facility financing obligation																							0	-4,420,000			-3,000,000				0	0
issuance cost associated with midcap credit facility																							0
repurchase of warrants
issuance cost associated with promissory notes
issuance of common stock for acquisition of in-process research and development
payment on promissory notes through issuance of common stock
payment on interest of promissory notes through issuance of common stock
payment of senior convertible notes through common stock issuance																							0
payment of interest on senior convertible notes through common stock issuance																			0	144,000	0	144,000	0	537,000	4,000	534,000
issuance of warrants associated with midcap credit facility
receivable from at the market offering																			-348,000	104,000
addition of right-of-use assets upon adoption of new lease guidance																							0	0
payment of facility obligation through common stock issuance																							0
accrued interest on promissory notes
payment of principal on senior convertible notes through common stock issuance																				0
impairment of commitment asset																						1,521,000
exercise of stock options																						8,000	74,000	32,000
payment of employment taxes related to vested restricted stock units																						-325,000						0	-103,000	-81,000	-17,000	-22,000	-13,000	-75,000	-4,000	-158,000	0	-3,000	-25,000	-1,015,000	-56,000	-762,000	-64,000	-26,721,000	-90,000	-33,000	-2,706,000	-1,647,000	-21,000	-427,000	-19,000	-482,000	-8,000	-397,000	-22,000	-26,000	-43,000
(gain) loss on extinguishment of debt																							0
gain on sale, abandonment/disposal or impairment of property and equipment
proceeds from sale of property and equipment																											110,000				0	0			0	0	0	17,000	4,000												4,000	0	41,000	32,000	30,000
issuance cost associated with mann group promissory notes
proceeds from public offering
proceeds from direct placement																																				0
issuance cost associated with public offering
issuance cost associated with direct placement																											0	0
right-of-use and other assets																								0	-16,000	-340,000
accrued interest - promissory notes
proceeds of senior convertible notes
payment of senior convertible notes
proceeds from direct placement of common stock																											0	0
proceeds from executive stock purchase plan
proceeds from issuance of common stock pursuant to at-the-market offering
issuance cost associated with in at-the-market offering
net cash (used) provided by financing activities																								65,495,000
net decrease in cash and cash equivalents and restricted cash																								17,205,000	-21,773,000	-36,627,000
property and equipment in progress in accounts payable																								-587,000	544,000	246,000
principal and interest payments on promissory notes through common stock issuance
payment of note obligations through common stock issuance																														9,407,000
accrued but unpaid debt issuance costs																												-10,000
interest on note payable to related party																									1,163,000	1,134,000	1,143,000	1,126,000	1,097,000	1,122,000
operating lease payments																									-304,000	-395,000
purchase of short-term investments																									-145,000	-24,764,000
proceeds from issuance of common stock pursuant to at-the-market issuance																											1,270,000	185,000	0	634,000
issuance cost of at-the-market transactions																												-8,000	0	-25,000
payment of note payable to related party through common stock issuance																												0	0	8,160,000
restricted stock unit award																										105,000
accrued but unpaid debt issuance costs related to note payable to related party																														75,000
addition of right-of-use assets																										5,192,000
change in fair value of warrant liability																															0	1,288,000	-147,000	-6,629,000
interest incurred through borrowings under sanofi loan facility																																			353,000	1,521,000	1,436,000	1,168,000
series a warrant issuance cost
(gain) loss on sale, abandonment/disposal or impairment of property and equipment																											-104,000																					0				0	-41,000	-32,000
gain on purchase commitments
receivable from sanofi																															0	0	0	30,557,000
deferred costs from commercial product sales																															138,000	-43,000	-28,000	-163,000	-30,000
deferred costs from collaboration																																			0
deferred payments from collaboration																													2,112,000	-63,000	-63,000	-62,000	-62,000	-63,000
deferred sales from collaboration																																			0	-26,882,000
loss on purchase commitments
net proceeds from sale of asset held for sale																															0	0
proceeds from public offering — common stock
proceeds from issuance of common stock																																			121,000	38,000	267,000	467,000
borrowings on note payable to related party
issuance costs of at-the-market transactions
payment of note obligations and interest through issuance of common stock
payment of note payable to related party through issuance of common stock
capitalization of interest on note payable to related party																																																			2,343,000	0
reclassification of deferred payments from collaboration to sanofi loan facility and loss share obligation																																			461,000	-290,000
reclassification of property and equipment to asset held for sale
reclassification of warrant liability to additional paid-in capital																															-13,000
deferred payments from collaborations
loss on sale, abandonment/disposal or impairment of property and equipment
payment of note obligations through common stock issuance, net of issuance costs
loss on foreign currency translation																														2,984,000		3,685,000	6,847,000	1,545,000
interest on note payable to principal stockholder																															1,174,000	1,173,000	721,000	714,000
(gain) loss on purchase commitments
receivable from collaboration
milestone rights liability and other liabilities
proceeds from issuance of common stock under tel aviv stock exchange
issuance cost associated with the tel aviv stock exchange
exercise of warrants for common stock																																														1,938,000	44,977,000	20,862,000
payment of debt issuance costs on senior convertible notes
borrowings on note payable to principal stockholder																															0	0
capitalization of interest on note payable to principal stockholder																															0	0
gain on disposal of property and equipment																																0
warrant issuance cost
net decrease in cash and cash equivalents
repayment of facility financing obligation through issuance of common stock																																0
deferred revenue—net
reclassification of deferred costs from loss on purchase commitment to deferred costs from collaboration
deferred revenue - net																																		-1,575,000
net proceeds from sale of property and equipment																																		16,651,000
cost incurred for construction in progress included in accounts payable and accrued liabilities
series a warrant issuance costs
write-off of tranche b commitment asset
write-off of derivative liability																																											0	0
receivables from collaboration																																					144,000	-121,000	1,656,000	3,069,000	-466,000	46,154,000
proceeds from direct placement of common stock and warrants
issuance costs associated with direct placement																																			0
payment of notes payable to deerfield
issuance costs associated with the tel aviv stock exchange
payment of 2015 notes																																							0
payment of debt issuance costs on 2018 notes																																							0
proceeds from issuance of facility financing obligation and milestone rights
proceeds from issuance of tranche b of the facility financing obligation																																											0	0
interest paid in cash, net of amounts capitalized to construction in progress
payment of 2015 notes and interest through issuance of common stock																																							0
issuance of common stock pursuant to debt conversion by deerfield
depreciation and accretion																																				1,039,000	1,035,000	1,023,000	3,182,000	3,470,000	3,636,000	2,988,000	3,001,000	2,960,000	3,220,000	9,394,000	3,948,000	3,441,000	3,320,000	3,348,000
loss on disposal of property and equipment																																								15,000
interest on note payable to our principal stockholder
loss on foreign currency exchange																																				1,012,000	-341,000	2,364,000
warrant fair value adjustment																																				-13,185,000
series a warrant issuance costs included in financing
deferred payment from collaboration
principal payments on notes payable to deerfield
issuance costs of at-the-market issuance
adjustments to reconcile net income to net cash from (used) in operating activities:
changes in assets and liabilities:
purchase commitment loss - current
non-current purchase commitment loss
other liabilities																																						721,000	734,000	728,000	722,000	743,000	729,000	751,000	721,000	714,000
issuance costs associated with the direct placement
proceeds from issuance of common stock pursuant to atm issuance																																								12,486,000
deferred product costs from collaboration																																							0	-2,708,000	-4,580,000	-6,251,000
deferred product sales from collaboration																																						177,000	29,000	4,070,000	5,918,000	7,050,000
write-off tranche b commitment asset
foreign exchange loss
payment of 3.75% senior convertible notes due 2013
proceeds from issuance of facility financing obligation & milestone rights																																											0				40,000,000
facility financing obligation & milestone rights issuance costs																																															0
reduction of principal on note payable to principal stockholder upon issuance of common stock and exercise of warrants
interest paid through borrowings under sanofi loan facility
write off of derivative liability
income from sale of intellectual property
interest expense related to milestone payment
deferred up-front payment from collaboration agreement
proceeds from sale of intellectual property
proceeds from issuance of common stock and warrants
issuance costs of atm
issuance of common stock pursuant to conversion of facility financing obligation																																												0	7,500,000	86,000,000
reclassification of share-based awards to liability																																												42,889,000
tranche b commitment asset																																												0	-1,168,000	2,921,000
reclassification of deferred payments from collaboration to sanofi loan facility
issuance of common stock and warrants, net of issuance costs																																									6,652,000	6,168,000	1,547,000	17,951,000	19,159,000	1,463,000	49,933,000	297,000	2,113,000	78,000		0	-80,518,000	80,598,000
issuance of common stock for notes receivable
adjustments to reconcile net income to net cash provide by (used in) operating activities:
fair value of forward purchase contract																																																			13,248,000	0	-10,306,000	-1,705,000
common shares issued pursuant to litigation settlement
commitment to deliver common shares pursuant to litigation settlement
state research and development credit exchange receivable																																											752,000	-600,000	-83,000	-82,000	224,000	399,000	-79,000	-78,000	-20,000	-85,000	-93,000	-92,000	678,000	-100,000	1,325,000	-310,000
deferred cash payments from collaboration
payment of 2013 notes
payment of milestone rights
borrowings on notes payable to principal stockholder
forward purchase contracts contribution to additional paid-in capital
reclassification of forward purchase contracts to additional paid-in capital
reclassification of collaboration loan facility obligation
stock expense for shares issued pursuant to research agreement
accrued interest on investments, net of amortization of discounts																																																									-12,000
goodwill impairment
litigation settlement in stock
purchase of marketable securities																																																									-2,000,000	-15,901,000
sales and maturities of marketable securities																																																							0
collection of series c convertible preferred stock subscriptions receivable
issuance of series b convertible preferred stock for cash
cash received for common stock to be issued
repurchase of common stock
put shares sold to majority stockholder
borrowings under lines of credit
proceeds from notes receivables
principal payments on notes payable to principal stockholder
borrowings on notes payable
principal payments on notes payable
cash paid for income taxes
accretion on redeemable convertible preferred stock
issuance of common stock upon conversion of notes payable
increase in additional paid-in capital resulting from merger
issuance of put option by stockholder
put option redemption by stockholder
issuance of series c convertible preferred stock subscriptions
issuance of series a redeemable convertible preferred stock
conversion of series a redeemable convertible preferred stock
forward purchase contract contribution to apic
reclassification of forward purchase contract to apic
accrued interest on investments, net of amortization of premiums
principal payments on notes payable to our principal stockholder
borrowings on notes payable to related party																																																				5,000,000	0	6,250,000
principal payments on notes payable to related party
cancellation of principal on note payable to related party																																																							0	11,116,000
issuance of common stock and warrants for cash
borrowings on notes payable from related party
reduction of principal on note payable to related party upon issuance of common stock and warrants
reduction of principal on note payable to related party upon issuance of common stock
forward purchase contract contribution to additional paid-in capital																																																				0
reclassification of forward purchase contract to additional paid-in capital																																																				0
fair value adjustment of warrant liability																																																					-2,993,000	284,000
warrant liability																																																					1,000	7,631,000
issuance of common stock and warrants																																																							397,000	9,746,000
sales/ maturities of marketable securities																																																								3,828,000
stock—based compensation expense																																																									5,836,000
in—process research and development
discount on stockholder notes below market rate
non—cash compensation expense of officer resulting from stockholder contribution
accrued interest expense on notes payable to stockholders
non—cash interest expense
accrued interest on notes receivable
loss on available—for—sale securities
sales of marketable securities																																																									17,800,000	15,350,000
deposit for purchase related to pfizer agreement																																																									-10,000,000
borrowings on notes payable from principal stockholder																																																									60,000,000
increase in additional paid—in capital resulting from merger
loss on sale and abandonment/disposal of property and equipment
non-cash compensation expense of officer resulting from stockholder contribution
non-cash interest expense
proceeds from notes receivable
noncash construction in progress
noncash transfer from fixed assets to other current assets
(gain)/loss on sale and abandonment/disposal of property and equipment
accrued interest on notes
payment of deferred compensation
restricted cash
notes receivable by stockholder issued to officers
loss/(gain) on sale and abandonment/disposal of property and equipment
state r&d credit exchange receivable
issuance of common stock for cash
payable to stockholder
net (decrease)/increase in cash and cash equivalents
non-cash compensation to officers
stock issued for services
notes receivable by stockholder to officers
conversion of series b convertible preferred stock
conversion of series c convertible preferred stock

We provide you with 20 years of cash flow statements for MannKind stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MannKind stock. Explore the full financial landscape of MannKind stock with our expertly curated income statements.

The information provided in this report about MannKind stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.